[The interference in correlated molecular mechanism obtained multi-drug resistance of mouse S180's tumour cell for different alkaloid].
OBJECTIVE
To observe the base of the interference in correlated biotic active matter obtained multi-drug resistance induced by chemotherapy for different alkaloid, and to supervise the use in clinic to restrain the multi-drug resistant of chemotherapy, and thereby to improve the curative effect.


METHODS
After bestowing subter-dosage unite chemotherapeutant to ascites S180 mouse to set up the mouse models of multi-drug resistance of S180 tumour cell, and giving the mouse matrine, terandrine, oxymatrine and berberine hydrooh loride for 4 weeks, the P170, LRP, TOPOII, Fas and apoposis were determined by flow cytometry.


RESULTS
Matrine and terandrine could obviously reduce the express of P170, LRP and the activation of TOPOII, and increase the ratio of the express of Fas and the apoposis of drug resistant tumour cell. And at the same time it could obviously reduce the express of intercellular adhesion molecule(CD54).


CONCLUSIONS
Matrine and terandrine can interfere in MDR which results from chemotherapeutics by the adjustment of correlated biotic active matter, besides, the different degree of alkaloid effect with different configuration.
Li
Gui-hai
GH
Shandong Academy of Traditional Chinese Medicine, Jinan, China. 995800ghli@163.com
Pan
Cheng-ye
CY
Sun
Fu-jun
FJ
Yin
Ge-ping
GP
Wang
Xue-rong
XR
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism*; D000470:Alkaloids / Q000302:isolation & purification / Q000494:pharmacology*; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D044182:Benzylisoquinolines / Q000302:isolation & purification / Q000494:pharmacology*; D001600:Berberine Alkaloids / Q000302:isolation & purification / Q000494:pharmacology; D004250:DNA Topoisomerases, Type II / Q000378:metabolism; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D005260:Female; D008297:Male; D051379:Mice; D010946:Plants, Medicinal / Q000737:chemistry; D011807:Quinolizines / Q000302:isolation & purification / Q000494:pharmacology*; D011897:Random Allocation; D012510:Sarcoma 180 / Q000378:metabolism / Q000473:pathology*; D014407:Tumor Cells, Cultured; D020394:Vault Ribonucleoprotein Particles / Q000378:metabolism; D019014:fas Receptor / Q000378:metabolism; D000093842:Matrines; D000099187:Major Vault Protein
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000470:Alkaloids; D044182:Benzylisoquinolines; D001600:Berberine Alkaloids; D004250:DNA Topoisomerases, Type II; D011807:Quinolizines; D020394:Vault Ribonucleoprotein Particles; D019014:fas Receptor; D000093842:Matrines; D000099187:Major Vault Protein; C491899:Fas protein, mouse; C009438:tetrandrine; C037573:oxymatrine